Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Condition: Cervical Squamous Cell Carcinoma; Recurrent Cervical Cancer
MeSH terms: Carcinoma; Carcinoma, Squamous Cell; Recurrence
Intervention: bevacizumab; laboratory biomarker analysis
Intervention description: Given IV; Correlative studies
Intervention MeSH terms: Bevacizumab; Antineoplastic Agents, Immunological; Antibodies; Immunoglobulins; Antibodies, Monoclonal
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 50.0
Sex: Female
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This phase II trial is to see if bevacizumab works in treating patients who have persistent
      or recurrent cancer of the cervix. Monoclonal antibodies, such as bevacizumab, can block
      cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
      Others find cancer cells and help kill them or deliver cancer-killing substances to them.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed persistent or recurrent squamous cell carcinoma (SCC) of the
             cervix

          -  Patients must have received at least 1, but no more than 2, prior cytotoxic
             chemotherapy regimens for advanced, metastatic, or recurrent SCC of the cervix

               -  Chemotherapy administered as a radio-sensitizer does not count as 1 regimen

          -  Documented disease progression

          -  At least 1 unidimensionally measurable lesion*

               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

          -  No tumor involving major blood vessels

          -  No history or physical evidence of CNS disease, including primary or metastatic brain
             tumor

          -  Ineligible for a higher priority Gynecological Oncology Group (GOG) protocol (if one
             exists), including any active GOG phase III protocol for the same patient population

          -  Performance status - GOG 0-2 (if received 1 prior regimen)

          -  Performance status - GOG 0-1 (if received 2 prior regimens)

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  No known bleeding disorder or coagulopathy

          -  No other active bleeding or pathologic condition that would confer a high risk of
             bleeding

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  SGOT ≤ 2.5 times ULN

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  INR ≤ 1.5 (or 2-3 for patients on a stable dose of therapeutic warfarin or low
             molecular weight heparin)

          -  PTT < 1.2 times control

          -  Creatinine ≤ 1.5 times ULN

          -  Creatinine clearance > 60 mL/min

          -  No proteinuria

               -  Urine protein < 1+ on dipstick or < 30 mg/dL

               -  Urine protein < 1000 mg by 24-hour urine collection

          -  No clinically significant cardiovascular disease

          -  No uncontrolled hypertension

          -  No myocardial infarction or unstable angina within the past 6 months

          -  No New York Heart Association grade II-IV congestive heart failure

          -  No serious cardiac arrhythmia requiring medication

          -  No grade II or greater peripheral vascular disease

          -  No history of stroke within the past 5 years

          -  No greater than grade 1 sensory or motor neuropathy

          -  No active infection requiring parenteral antibiotics

          -  No serious nonhealing wound, ulcer, or bone fracture

          -  No history or physical evidence of seizures not controlled with standard medical
             therapy

          -  No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
             human antibodies

          -  No other invasive malignancy within the past 5 years except nonmelanomatous skin
             cancer

          -  No significant traumatic injury within the past 4 weeks

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for at least 3 months
             after completion of study treatment

          -  No prior bevacizumab

          -  At least 3 weeks since prior immunologic agents for SCC of the cervix

          -  See Disease Characteristics

          -  Recovered from prior chemotherapy

          -  No prior non-cytotoxic chemotherapy for persistent or recurrent disease

          -  At least 1 week since prior hormonal therapy for SCC of the cervix

          -  Concurrent hormone replacement therapy allowed

          -  See Disease Characteristics

          -  Recovered from prior radiotherapy

          -  Recovered from recent prior surgery

          -  At least 4 weeks since prior major surgical procedure or open biopsy

          -  At least 1 week since prior placement of vascular access device or core biopsy

          -  No concurrent major surgical procedure

          -  At least 3 weeks since other prior therapy for SCC of the cervix

          -  No prior anticancer therapy that would preclude study therapy

          -  No concurrent anticoagulants other than those required to maintain the patency of
             indwelling IV catheters

          -  No concurrent chronic daily aspirin greater than 325 mg/day or other nonsteroidal
             anti-inflammatory medications that are known to inhibit platelet function at doses
             used for chronic inflammatory diseases